Cardiovascular diseases (CVD), arterial hypertension (AH) and diabetes mellitus (DM) in a cohort of 609 COPD patients: Associations with the new GOLD classification 2011 Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations Year: 2013
Impact of borderline (BL) pulmonary hypertension (PH) in chronic lung diseases (CLD). Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
Effect of roflumilast (ROF) on glucose levels in patients with COPD and diabetes mellitus type 2 (DM2) Source: Annual Congress 2010 - COPD: management Year: 2010
Increased prevalence of obstructive airways disease (OAD) in patients with ischemic heart disease (IHD) and hypertension (HT) Source: Eur Respir J 2007; 30: Suppl. 51, 122s Year: 2007
Frequency and pecularities of flow pulmonary tuberculosis (PT) in patients with different forms of diabetes mellitus (DM) in up-to-date conditions Source: Eur Respir J 2002; 20: Suppl. 38, 363s Year: 2002
Diabetes melittus (DM) risk for pulmonary tuberculosis (PTB) Source: Eur Respir J 2004; 24: Suppl. 48, 421s Year: 2004
TGF-β1 type II receptor (TGF-βRII) expression in pulmonary arteries of patients with severe COPD Source: Eur Respir J 2005; 26: Suppl. 49, 96s Year: 2005
Relationship between pulmonary hypertension (PH) and lung function in severe COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 252s Year: 2001
Pulmonary arterial hypertension (PAH) among end state renal disease (ESRD) patients under chronic hemodyalisis (HD) Source: Eur Respir J 2007; 30: Suppl. 51, 345s Year: 2007
Arterial hypertension (AH) and endothelial function (EF) in patients with COPD Source: Annual Congress 2011 - COPD mechanisms Year: 2011
Endothelin receptor antagonist (ETRA) bosentan (B) in patients with severe pulmonary hypertension (PH) associated with pulmonary disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010
Relevance of pulmonary hypertension (PH) in COPD: prevalence of resting and exercise-induced PH at different GOLD stages Source: Annual Congress 2007 - Pulmonary vascular involvement in smoking and respiratory diseases Year: 2007
Inflammatory biomarkers in patients with COPD and pulmonary hypertension (PH). Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019
Role of BMI in the clinical course of COPD patients with type 2 diabetes mellitus Source: International Congress 2018 – COPD and extrapulmonary comorbidities Year: 2018
Influence of bronchodilators on pulmonary hypertension (PH) in patients with moderate and severe chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 310s Year: 2005
Treatment of pulmonary hypertension (PH) and sickle cell disease (SCD) with sildenafil (SILD) therapy (walk-phasst): interim report Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009
Is there any characteristics difference between pulmonary tuberculosis patients with and without diabetes mellitus type 2? Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009
HRQoL in adult patients with Eisenmenger syndrome (ES) compared to patients with primary pulmonary hypertension (PPH) or post-embolic pulmonary hypertension (PEPH) Source: Eur Respir J 2002; 20: Suppl. 38, 455s Year: 2002
Study of the connection between COPD, bronchial asthma and diabetes mellitus types 1 and 2 Source: Annual Congress 2009 - Asthma and comorbid conditions Year: 2009
The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD) Source: Eur Respir J 2005; 26: Suppl. 49, 560s Year: 2005